Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Sezary Syndrome 2Recurrence 2Prostatic Neoplasms 2Neoplasms 2Mycosis Fungoides 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Hematologic Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Soft Tissue Neoplasms 1Sarcoma 1Respiratory Distress Syndrome 1Radiation Pneumonitis 1Primary Myelofibrosis 1

Interventions

pembrolizumab 2Sunitinib 2sitravatinib 1pazopanib 1atezolizumab 1aldesleukin 1Nivolumab 1Nephrectomy 1Metastasectomy 1LY2510924 1Immunoglobulin G 1Cytoreduction Surgical Procedures 1Axitinib 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Clear-cell metastatic renal cell carcinoma × Immunoglobulin G × Clear all
NCT03260504 2025-12-08

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

University of Washington

Phase 1 Terminated
6 enrolled 11 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡